Gufic BioSciences
284.60
-4.65(-1.61%)
Market Cap₹2,854.04 Cr
PE Ratio57.65
IndustryHealthcare
Company Performance:
1D-1.61%
1M+1.48%
6M-14.44%
1Y-24.13%
5Y+110.35%
View Company Insightsright
More news about Gufic BioSciences
13Feb 26
Gufic Biosciences Releases Q3FY26 Investor Presentation with Financial Results
Gufic Biosciences reported Q3FY26 revenue of ₹231.10 crore, up 11.22% year-on-year, though profit margins declined with PAT falling to ₹15.60 crore. The company's Indore facility achieved 30% capacity utilization with production capabilities across multiple injectable formats, while maintaining strong regulatory compliance across its diversified pharmaceutical platform.
 no imag found
20Jan 26
Gufic Biosciences Receives Income Tax Demand of ₹4.33 Crores for Assessment Year 2024-25
Gufic Biosciences Limited received a ₹4.33 crores income tax demand for Assessment Year 2024-25 due to expenditure disallowance under Section 143(1)(a). The company received the December 22, 2025 order on January 19, 2026, and plans to file an appeal with the Commissioner of Income Tax (Appeal). Management remains confident of a favorable outcome based on legal advice and case merits.
 no imag found
27Dec 25
Gufic Biosciences Receives GST Penalty Order of ₹15.64 Lakh for FY2018-19 to FY2022-23
Gufic BioSciences has been issued a GST penalty order of ₹15,64,052 by tax authorities for the period FY2018-19 to FY2022-23. The penalty includes ₹15,35,080 for excess Input Tax Credit claims and ₹28,972 for short payment of tax liability. The company plans to contest the penalties by filing an appeal and believes there will be no material impact on its financial operations or business activities.
 no imag found
13Aug 25
Gufic Biosciences Reports Q1 Results: Revenue Up, Profit Down Amid Rising Costs
Gufic BioSciences, an Indian pharmaceutical company, released its Q1 financial results. Consolidated revenue increased by 10.3% to ₹223.72 crore, up from ₹202.81 crore in the previous year. However, net profit declined by 37.3% to ₹13.07 crore from ₹20.86 crore. EBITDA decreased by 9.8% to ₹32.30 crore, with the EBITDA margin falling by 339 basis points to 14.25%. The company faced increased material costs, higher employee benefits expenses, and doubled finance costs. Gufic BioSciences continues to operate solely in the pharmaceuticals segment.
 no imag found
30May 25
Gufic Biosciences Reports Mixed Q4 Results: Revenue Up, Profits Down
Gufic Biosciences' Q4 financial results show a 5.13% increase in revenue to ₹2.05 billion, but a significant decline in profitability. EBITDA fell to ₹266.00 million from ₹342.30 million year-over-year, with EBITDA margin dropping to 12.99% from 17.55%. Net profit sharply decreased to ₹80.00 million from ₹200.00 million in the previous year. The company faces challenges in maintaining profit margins despite revenue growth.
 no imag found
Gufic BioSciences
284.60
-4.65
(-1.61%)
1 Year Returns:-24.13%
Industry Peers
Sun Pharmaceutical
1,808.30
(+1.66%)
Divis Laboratories
6,502.50
(-0.48%)
Torrent Pharmaceuticals
4,185.10
(-1.10%)
Dr Reddys Laboratories
1,322.90
(-0.52%)
Cipla
1,309.60
(-0.61%)
Lupin
2,305.20
(-0.27%)
Mankind Pharma
2,246.70
(-0.45%)
Zydus Life Science
891.90
(-2.08%)
Aurobindo Pharma
1,389.50
(-0.52%)
Glenmark Pharmaceuticals
2,406.30
(-0.31%)